Patton named CEO of OneOncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeff Patton was named chief executive officer of OneOncology. Patton has been Acting CEO and president of Physician Services since February.

Jeff Patton

OneOncology includes five practices throughout the U.S., represents over 400 providers, and cares for approximately 250,000 patients annually at 160 sites of care. OneOncology partner practices deliver integrated oncology care services including screening and diagnosis, clinical trials, therapies, and survivorship or end-of-life care. A main responsibility of OneOncology is to help its partner practices expand services in cancer care.

“We formed OneOncology in 2018 with the idea that with physician leadership, common technology platforms, and access to capital, practices could have both the necessary scale and local decision-making authority needed to not only survive but thrive in today’s marketplace,” Patton said in a statement. “Today, as practices grapple with COVID-19 and plan for caring for patients post peak, the ideas that brought us together are exactly what will propel our future growth.”

Patton will continue as the executive chairman of the board at Tennessee Oncology.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login